# US 2024/0197782 A1 · Methods and compositions for genetic modification and therapeutic use of immune cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197782 A1
- Document ID: US20240197782A1
- Status: Published application
- Kind: A1
- Application number: 18/555,846
- Filed: 2022-04-20
- Published: 2024-06-20
- Earliest claimed: 2021-04-20
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Cassian YEE; Yongming XUE; Farah HASAN
- Web page: https://patentgrep.com/patent/US20240197782A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4273: {Glycoprotein 100 [Gp100]}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 14/495: Transforming growth factor [TGF]
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 5/0636: {T lymphocytes}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C07K 2319/03: containing a transmembrane segment
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Aspects of the present disclosure relate to methods and compositions for genetic modification of immune cells to generate immune cells that do not secrete TGF-β1. Also disclosed are methods for use of such genetically modified immune cells, including immunotherapeutic methods for the treatment of cancer. Further aspects of the disclosure are directed to human CD8+ cells comprising a genetic modification that prevents the cells from secreting TGF-β1.

## Claims

### Claim 1

A method for treating a subject having cancer, the method comprising administering to the subject a human CD8+ T cell that does not secrete TGF-β1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human CD8+ T cell does not express TGF-β1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human CD8+ T cell expresses a mutant TGF-β1 protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein the human CD8+ T cell was derived from a CD8+ T cell from the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the human CD8+ T cell from the subject is a tumor-infiltrating lymphocyte.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1-5, wherein the human CD8+ T cell comprises a mutation of TGFB1.

### Claim 7 (depends on 6)

The method of claim 6, where the mutation is a frameshift mutation.

### Claim 8 (depends on 6)

The method of claim 6, wherein the mutation is a nonsense mutation.

### Claim 9 (depends on 6)

The method of claim 6, wherein the mutation is a modification of a region of exon 1 of TGFB1.

### Claim 10 (depends on 9)

The method of claim 9, wherein the region of exon 1 comprises the sequence of SEQ ID NO:1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the cancer is melanoma.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any of claims 1-11, wherein the cancer is recurrent cancer.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any of claims 1-12, wherein the subject was previously treated for cancer with a previous treatment.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject was determined to be resistant to the previous treatment.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any of claims 1-14, wherein the method comprises administering to the subject a population of human CD8+ T cells comprising the human CD8+ T cell, wherein each cell of the population of human CD8+ T cells does not secrete TGF-β1.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 1-15, further comprising administering an additional cancer therapy.

### Claim 17 (depends on 16)

The method of claim 16, wherein the additional cancer therapy is a chemotherapy, radiotherapy, or immunotherapy.

### Claim 18

A method for genetically modifying a human CD8+ T cell, the method comprising introducing into the cell a Cas nuclease and a guide RNA targeted to TGFB1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the guide RNA is targeted to a region of exon 1 of TGFB1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the region of exon 1 comprises the sequence of SEQ ID NO:1.

### Claim 21 (depends on 18, 19, 20)

The method of any of claims 18-20, wherein the Cas nuclease is Cas9.

### Claim 22 (depends on 18, 19, 20)

The method of any of claims 18-20, wherein the Cas nuclease is Cas12a.

### Claim 23 (depends on 18, 19, 20, 21, 22)

The method of any of claims 18-22, wherein a mutation is generated in TGFB1 in the cell.

### Claim 24 (depends on 23)

The method of claim 23, wherein the mutation is generated using the Cas nuclease.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, where the mutation is a frameshift mutation.

### Claim 26 (depends on 23, 24)

The method of claim 23 or 24, wherein the mutation is a nonsense mutation.

### Claim 27 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any of claims 18-26, wherein the Cas nuclease and the guide RNA are introduced into the cell via transfection.

### Claim 28 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any of claims 18-26, wherein the Cas nuclease and the guide RNA are introduced into the cell via electroporation.

### Claim 29 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 18-28, further comprising obtaining the human CD8+ T cell from a subject.

### Claim 30 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any of claims 18-29, wherein the human CD8+ T cell is a tumor-infiltrating lymphocyte.

### Claim 31

A method for treating a subject having cancer, the method comprising:
(a) modifying immune cells from the subject to generate genetically modified immune cells that do not secrete TGF-β1; and
(b) administering the genetically modified immune cells to the subject.

### Claim 32 (depends on 31)

The method of claim 31, wherein the genetically modified immune cells do not express TGF-β1.

### Claim 33 (depends on 31)

The method of claim 31, wherein the genetically modified immune cells express a mutant TGF-β1 protein.

### Claim 34 (depends on 31)

The method of claim 31, wherein secretion of TGF-β1 is undetectable in the genetically modified immune cells.

### Claim 35 (depends on 31)

The method of claim 31, wherein secretion of TGF-β1 is decreased by at least 80% in the genetically modified immune cells compared to a population of control or reference cells.

### Claim 36 (depends on 31)

The method of claim 31, wherein secretion of TGF-β1 is decreased by at least 90% in the genetically modified immune cells compared to a population of control or reference cells.

### Claim 37 (depends on 31)

The method of claim 31, wherein expression of TGF-β1 is undetectable in the genetically modified immune cells.

### Claim 38 (depends on 31)

The method of claim 31, wherein expression of TGF-β1 is decreased by at least 80% in the genetically modified immune cells compared to a population of control or reference cells.

### Claim 39 (depends on 31)

The method of claim 31, wherein expression of TGF-β1 is decreased by at least 90% in the genetically modified immune cells compared to a population of control or reference cells.

### Claim 40 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 31-39, wherein the immune cells are natural killer T cells.

### Claim 41 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 31-39, wherein the immune cells are modified to express a cloned T cell receptor (TCR) or a chimeric antigen receptor (CAR).

### Claim 42 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 31-39, wherein the immune cells are engineered CAR-T cells or engineered TCR-T cells.

### Claim 43 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 31-39, wherein the immune cells are T cells.

### Claim 44 (depends on 43)

The method of claim 43, wherein the T cells are CD4+ T cells.

### Claim 45 (depends on 43)

The method of claim 43, wherein the T cells are CD8+ T cells.

### Claim 46 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any of claims 31-45, wherein the immune cells are tumor-infiltrating lymphocytes.

### Claim 47 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any of claims 31-46, wherein modifying the immune cells comprises generating a mutation in TGFB1.

### Claim 48 (depends on 47)

The method of claim 47, where the mutation is a frameshift mutation.

### Claim 49 (depends on 47)

The method of claim 47, wherein the mutation is a nonsense mutation.

### Claim 50 (depends on 47, 48, 49)

The method of any of claims 47-49, wherein the mutation is a mutation in exon 1 of TGFB1.

### Claim 51 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any of claims 31-50, wherein modifying the immune cells comprises targeting a region of exon 1 of TGFB1 using a Cas nuclease and a guide RNA.

### Claim 52 (depends on 51)

The method of claim 51, wherein the region of exon 1 comprises SEQ ID NO:1.

### Claim 53 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any of claims 31-52, wherein the subject is a human subject.

### Claim 54 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any of claims 31-53, further comprising, prior to (a), obtaining the immune cells from the subject.

### Claim 55 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any of claims 31-54, wherein the cancer is melanoma.

### Claim 56 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any of claims 31-55, wherein the cancer is recurrent cancer.

### Claim 57 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any of claims 31-56, wherein the subject was previously treated for cancer with a previous treatment.

### Claim 58 (depends on 57)

The method of claim 57, wherein the subject was determined to be resistant to the previous treatment.

### Claim 59 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any of claims 31-58, further comprising administering an additional cancer therapy.

### Claim 60 (depends on 59)

The method of claim 59, wherein the additional cancer therapy is a chemotherapy, radiotherapy, or immunotherapy.

### Claim 61

A human immune cell comprising a genetic modification that prevents the cell from secreting TGF-β1.

### Claim 62 (depends on 61)

The cell of claim 61, wherein the immune cell is a T cell.

### Claim 63 (depends on 62)

The cell of claim 62, wherein the T cell is a CD8+ T cell.

### Claim 64 (depends on 62)

The cell of claim 62, wherein the T cell is a CD4+ T cell.

### Claim 65 (depends on 61)

The cell of claim 61, wherein the immune cell is a natural killer T cell.

### Claim 66 (depends on 61)

The cell of claim 61, wherein the immune cell expresses a cloned TCR or a CAR.

### Claim 67 (depends on 61)

The cell of claim 61, wherein the immune cell is an engineered CAR-T cell or an engineered TCR-T cell.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66, 67)

The cell of any of claims 61-67, wherein the genetic modification is a frameshift mutation of TGFB1.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66, 67)

The cell of any of claims 61-67, wherein the genetic modification is a nonsense mutation of TGFB1.

### Claim 70 (depends on 61, 62, 63, 64, 65, 66, 67)

The cell of any of claims 61-67, wherein the genetic modification is a deletion of TGFB1.

### Claim 71 (depends on 61, 62, 63, 64, 65, 66, 67)

The cell of any of claims 61-67, wherein the genetic modification comprises a modification of a region of exon 1 of TGFB1.

### Claim 72 (depends on 71)

The cell of claim 71, wherein the region of exon 1 comprises SEQ ID NO:1.

### Claim 73 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The cell of any of claims 61-72, wherein the cell is or was derived from a tumor-infiltrating lymphocyte.

### Claim 74 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

A population of human immune cells comprising the human immune cell of any of claims 61-73.

### Claim 75 (depends on 74)

The population of human immune cells of claim 74, wherein secretion of TGF-β1 is undetectable in the population of human immune cells.

### Claim 76 (depends on 74)

The population of human immune cells of claim 74, wherein secretion of TGF-β1 is decreased by at least 80% in the population of human immune cells compared to a population of control or reference cells.

### Claim 77 (depends on 74)

The population of human immune cells of claim 74, wherein secretion of TGF-β1 is decreased by at least 90% in the population of human immune cells compared to a population of control or reference cells.

### Claim 78 (depends on 74, 75, 76, 77)

The population of human immune cells of any of claims 74-77, wherein expression of TGF-β1 is undetectable in the population of human immune cells.

### Claim 79 (depends on 74, 75, 76, 77)

The population of human immune cells of any of claims 74-77, wherein expression of TGF-β1 is decreased by at least 80% in the population of human immune cells compared to a population of control or reference cells.

### Claim 80 (depends on 74, 75, 76, 77)

The population of human immune cells of any of claims 74-77, wherein expression of TGF-β1 is decreased by at least 90% in the population of human immune cells compared to a population of control or reference cells.

### Claim 81 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

A pharmaceutical composition comprising (a) the human immune cell of any of claims 61-73 or the population of human immune cells of any of claims 74-80 and (b) a pharmaceutically acceptable excipient.

### Claim 82 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

A method for treating a subject having cancer comprising administering to the subject the human immune cell of any of claims 61-73, the population of human immune cells of any of claims 74-80, or the pharmaceutical composition of claim 81.

### Claim 83 (depends on 82)

The method of claim 82, wherein the cancer is melanoma.

### Claim 84 (depends on 82, 83)

The method of claim 82 or 83, wherein the cancer is recurrent cancer.

### Claim 85 (depends on 82, 83, 84)

The method of any of claims 82-84, wherein the subject was previously treated for cancer with a previous treatment.

### Claim 86 (depends on 82, 83, 84, 85)

The method of any of claims 82-85, wherein the subject was determined to be resistant to the previous treatment.

### Claim 87 (depends on 82, 83, 84, 85, 86)

The method of any of claims 82-86, wherein the human immune cell was derived from a cell from the subject.
